|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Global epidemiology of sexually transmitted diseases显示文摘性传播疾病(性传播疾病) 在在在在年轻成年女人开发国家和讨厌的疾病的第二个主要原因的年轻成年男性的讨厌的疾病的开始的十个原因之中。青少年和年轻成年人(15-24 岁) 仅仅完成 25% 性活跃的人口,但是代表几乎 50% 所有新获得的性传播疾病。一般来说,性传播疾病是流行病并且介绍庞大的健康和经济后果。为性传播疾病的足够的屏蔽应该在世界的每部分在一个平淡的基础上被做。许多性传播疾病是无征状的因此装对控制困难。性传播疾病报导的目的是保证被感染的人将快速被诊断并且适当地对待控制感染并且也的传播以便搭挡们被通知,测试并且适当地对待。报导性传播疾病的案例在美国代表仅仅可报告的性传播疾病感染的 50%-80% ,这被估计,反映有限屏蔽并且低疾病报导。当它经常导致少年怀孕和 HIV/AIDS,高风险的性行为是这个过程的一个高度贡献的因素。对这行为的一可能的解释是人们没关于性传播疾病的传播有足够的信息或忽略为安全的性要求的措施。世界范围的约 60% 新 HIV 感染发生在年轻人。在少年之中的高风险的行为的频率可以被机会也影响从事他们,特别地他们由成年人是无指导的时间的数量。在诊断并且对待这些病人,然而,我们能有效地阻止 HIV/AIDS 的传播。感染性传播疾病的个人比 uninfected 个人更多半是 5-10 时间通过性接触获得或播送 HIV。碎生殖道衬里或皮为 HIV 创造侵入门户,,因此有另外的性传播疾病的感染 HIV 的个人是更可能的在他们的生殖器的分泌物流 HIV。迄今为止,避孕套是为为对性传播疾病的保护的男性可得到的最有效的方法。性传播疾病,和预防能是这个过程的钥匙,对控制重要。预防能通过这些病人和他们的搭挡的人口,征兆、无征状的人的鉴定,和有效诊断和治疗的教育被完成。 | Carlos T. Da Ros Caio da Silva Schmitt | 2008 | Asian Journal of Andrology2008，10，1： | 38 |
| 2 | Molecular basis and management of gastrointestinal stromal tumors显示文摘Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for firstand secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib’s role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatiniband sunitinib-resistant GISTs. | Ulas D Bayraktar Soley Bayraktar Caio M Rocha-Lima | 2010 | World Journal of Gastroenterology2010，16，22： | 23 |
| 3 | Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer显示文摘In spite of advances made in the management of the other more common cancers of the gastrointestinal tract,significant progress in the treatment of pancreatic cancer remains elusive.Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease.Until recently,the only treatment with an impact on survival was surgery.In the palliative setting,gemcitabine(Gem) has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil.Since then,clinical trials have explored the pharmacokinetic modulation of Gem by fixed dose administration and the combination of Gem with other cytotoxic or the biologically'targeted'agents.However,promising trial results in small phaseⅡtrials have not translated into survival improvements in larger phaseⅢrandomized trials in the advanced disease setting.Two trials have recently reported modest survival improvements with the use of combination treatment with Gem and capecitabine(United Kingdom National Cancer Research GEMCAP trial) or erlotinib(National Cancer Institute of CanadaClinical Trials Group PA.3 trial) .This review will focus on the use of systemic therapy for advanced and metastatic pancreatic cancer,summarizing the results of several recent clinical trials and discuss their implications for clinical practice.We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer. | Soley Bayraktar Ulas Darda Bayraktar Caio Max Rocha-Lima | 2010 | World Journal of Gastroenterology2010，16，6： | 11 |
| 4 | Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma显示文摘Non-small-cell lung cancer(NSCLC)remains the leading cause of cancer-related death in both men and women in the United States.Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease.Improvements in overall survival and quality of life have been modest.Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics,thus changing the treatment paradigm for many NSCLC patients.In this review,we present a summary of many of the currently investigated biologic targets in NSCLC,discuss their current clinical trial status,and also discuss the potential for development of other targeted agents. | Soley Bayraktar Caio M Rocha-Lima | 2013 | World Journal of Clinical Oncology2013，4，2： | 8 |
| 5 | Molecular approaches for spinal cord injury treatment显示文摘Injuries to the spinal cord result in permanent disabilities that limit daily life activities.The main reasons for these poor outcomes are the limited regenerative capacity of central neurons and the inhibitory milieu that is established upon traumatic injuries.Despite decades of research,there is still no efficient treatment for spinal cord injury.Many strategies are tested in preclinical studies that focus on ameliorating the functional outcomes after spinal cord injury.Among these,molecular compounds are currently being used for neurological recovery,with promising results.These molecules target the axon collapsed growth cone,the inhibitory microenvironment,the survival of neurons and glial cells,and the re-establishment of lost connections.In this review we focused on molecules that are being used,either in preclinical or clinical studies,to treat spinal cord injuries,such as drugs,growth and neurotrophic factors,enzymes,and purines.The mechanisms of action of these molecules are discussed,considering traumatic spinal cord injury in rodents and humans. | Fernanda Martins de Almeida Suelen Adriani Marques Anne Caroline Rodrigues dos Santos Caio Andrade Prins Fellipe Soares dos Santos Cardoso Luiza dos Santos Heringer Henrique Rocha Mendonça Ana Maria Blanco Martinez | 2023 | Neural Regeneration Research2023，18，1： | 3 |
| 6 | Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness显示文摘最近,没有腹的疾病或小麦过敏症的证据,对饮食的面筋敏感的世界范围的病人的增加的数字贡献了定义为非腹的面筋敏感的新面筋相关的症候群的鉴定。我们关于这症候群的知识仍然正在缺乏,并且这症候群的许多方面仍然保持未知。它的致病是异构的,与为天生的免疫的一个公认的枢轴的角色;许多另外的因素也作出贡献,包括低档在肠的 microbiota 的肠的发炎,增加的肠的障碍功能和变化。面筋和其它小麦蛋白质例如淀粉酶胰岛素禁止者,是这症候群的主要扳机,但是富于沸腾的 monosaccharides 和 polyols 的一本食谱可以得到它的功能的胃肠的症状,这也被假设了。这个条件的传染病学远非被建立;它在一般人口的流行是高度可变的,从 0.63 % ;到 6 %。从一个临床的观点,非腹的面筋敏感被一个宽数组描绘胃肠并且立即在面筋的摄取以后发生并且当面筋从食谱被撤退时,改善或消失的 extraintestinal 症状。当面筋是 reintroduced 时,这些症状复发。因为诊断 biomarkers 还没被识别了,一个双窗帘控制安慰剂的面筋挑战当前是有最高的精确性的诊断方法。未来研究被需要关于非腹的面筋敏感,有全球接受,但是有仅仅一些必然的一个条件和许多未解决的问题产生更多的知识。 | Umberto Volta Giacomo Caio Francesco Tovoli Roberto De Giorgio | 2013 | Cellular & Molecular Immunology2013，10，5： | 3 |
| 7 | 中国参与全球治理的七大建议显示文摘 | Caio Koch-Weser | 2006 | 国际经济评论2006，，4： | 3 |
| 8 | Resection of a rapid-growing 40-cm giant liver hemangioma显示文摘Hemangiomas are the most frequent benign tumors of the liver. Most hemangiomas are asymptomatic and therefore largely diagnosed only in routine screening tests. Usually they are small and require no specific treatment. In some situations they can reach great dimensions, causing some discomfort to the patient. Resection of liver hemangioma is indicated in cases of great dimension tumors causing symptoms such as pain, nausea or bloating caused by compression of adjacent organs. We report a case of a rare giant hemangioma with rapid growth in short time:a 50 year old female reported to our institution with a 40 cm giant liver hemangioma and then underwent a left hepatectomy. | Andreas JM Koszka Fabio G Ferreira Caio GG de Aquino Maurício A Ribeiro André S Gallo Elisa MC Aranzana Luiz A Szutan | 2010 | World Journal of Hepatology2010，2，7： | 3 |
| 9 | EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video)显示文摘 | Gil Ascunce Afonso Ribeiro Isildinha Reis Caio Rocha-Lima Danny Sleeman Jaime Merchan Joe Levi | 2011 | Gastrointestinal Endoscopy2011，，2： | 2 |
| 10 | Absence of galectin-3 attenuates neuroinflammation improving functional recovery after spinal cord injury显示文摘After spinal cord injury(SCI),a cascade of events begins.At first,there is physical damage with disruption of the blood-brain barrier(BBB)and the integrity of the nervous tissue.The disruption of central nervous system(CNS)BBB alters the endothelial permeability,the protein and chemokines expression and the propensity to release in situ inflammatory cytokines,overcoming anti-inflammatory signals,facilitating the | Caio Andrade Prins Fernanda Martins Almeida Ana Maria Blanco Martinez | 2016 | Neural Regeneration Research2016，11，1： | 2 |
| 11 | Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma显示文摘 | Govindarajan Narayanan Peter J. Hosein Geetika Arora Katuzka J. Barbery Tatiana Froud Alan S. Livingstone Dido Franceschi Caio M. Rocha Lima Jose Yrizarry | 2012 | Journal of Vascular and Interventional Radiology2012，，12： | 2 |
| 12 | Superficial mycoses at the Hospital do Servidor Phblico Municipal de Sao Paulo between 2005 and 2011显示文摘 | Nihon Di Chiacchio Celso Luiz Madeira Caio Rosa Hu- maire | 2014 | An Bras Dermatol2014，89，1： | 1 |
| 13 | Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor显示文摘 | Caio S. R. Nahas M.D. Jinru Shia M.D. Romane Joseph M.D. Deborah Schrag M.D. Bruce D. Minsky M.D. Martin R. Weiser M.D. Jose G. Guillem M.D. Phillip B. Paty M.D. David S. Klimstra M.D. Laura H. Tang M.D. W. Douglas Wong M.D. Larissa K. Temple M.D | 2007 | Diseases of the Colon & Rectum2007，，9： | 1 |
| 14 | New multi-phase catalytic systems based on tin compounds active for vegetable oil transesterification reaction 显示文摘 | Abreu F R Melquizedeque B Alves Caio C S | 2005 | Journal of Molecular catalysis A : Chenmical2005，227，： | 1 |
| 15 | Gemcitabine Doublets in Advanced Pancreatic Cancer: Should We Move On? 显示文摘 | Caio Max Sao Pedro Rocha Lima and Aurea Maria Flores | 2006 | J Clin Oncol2006，24，3： | 1 |
| 16 | Influence of an m-type throredoxin in maize on potyviral infection显示文摘 | SHI Y QIN H Y CAIO Y Y | 2011 | European Journal of Plant Pathology2011，131，2： | 1 |
| 17 | Carbapenem and muhidrug resis- tance in Gram-negative bacteria in a single centre in Italy : Considerations on in vitro assay of active drugs显示文摘 | Mezzatesta ML Caio C Gona F | 2014 | Int J Antimicrob Agents2014，44，2： | 1 |
| 18 | Fas, FasL, and cleaved caspases 8 and 3 in glioblastomas: A tissue microarray-based study显示文摘 | Fabiano P. Saggioro Luciano Neder Jo?o Norberto Stávale Aline Nazareth P. Paix?o-Becker Suzana M.F. Malheiros Fernando A. Soares José Eymard H. Pittella Caio César M.S. Matias Benedicto O. Colli Carlos Gilberto Carlotti Marcello Franco | 2013 | Pathology - Research and Practice2013，，： | 1 |
| 19 | Multieenter Evaluation of Resistace Patterns of Klebsiella Pneumoniae, Escherichia coli, Salmonella spp and Shigella spp isolated from Clinical Specimens in Brazil: RESISTNET Surveillance Program 显示文摘 | Carmen P O Rogerio N Caio M ct al | 2001 | The Brazilian Journal of Infections Diseases2001，5，1： | 1 |
| 20 | Detection of anticonduc- tive tissue autoantibodies in a patient with chronic intesti- nal pseudo-obstruction and sick sinus syndrome显示文摘 | Caio G Volta U Cerrato E | 2013 | Eur J Gastroenterol Hepatol2013，25，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员